Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer
- PMID: 11917105
- PMCID: PMC123712
- DOI: 10.1073/pnas.062047599
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer
Abstract
Intrastriatal delivery of the tyrosine hydroxylase gene by viral vectors is being explored as a tool for local delivery of L-dopa in animals with lesions of the nigrostriatal pathway. The functional effects reported using this approach have been disappointing, probably because the striatal L-dopa levels attained have been too low. In the present study, we have defined a critical threshold level of L-dopa, 1.5 pmol/mg of tissue, that has to be reached to induce any significant functional effects. Using new generation high-titer recombinant adeno-associated virus vectors, we show that levels of striatal L-dopa production exceeding this threshold can be obtained provided that tyrosine hydroxylase is coexpressed with the cofactor synthetic enzyme, GTP-cyclohydrolase-1. After striatal transduction with this combination of vectors, substantial functional improvement in both drug-induced and spontaneous behavior was observed in rats with either complete or partial 6-hydroxydopamine lesions of the nigrostriatal pathway. However, complete reversal of motor deficits occurred only in animals in which part of the striatal dopamine innervation was left intact. Spared nigrostriatal fibers thus may convert L-dopa to dopamine and store and release dopamine in a more physiologically relevant manner in the denervated striatum to mediate better striatal output-dependent motor function. We conclude that intrastriatal L-dopa delivery may be a viable strategy for treatment and control of adverse side effects associated with oral L-dopa therapy such as on-off fluctuations and drug-induced dyskinesias in patients with Parkinson's disease.
Figures





Similar articles
-
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.Brain. 2005 Mar;128(Pt 3):559-69. doi: 10.1093/brain/awh374. Epub 2005 Jan 19. Brain. 2005. PMID: 15659429
-
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.J Neurosci. 1998 Jun 1;18(11):4271-84. doi: 10.1523/JNEUROSCI.18-11-04271.1998. J Neurosci. 1998. PMID: 9592104 Free PMC article.
-
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.Hum Gene Ther. 2000 Jul 20;11(11):1509-19. doi: 10.1089/10430340050083243. Hum Gene Ther. 2000. PMID: 10945765
-
[Gene therapy for Parkinson's disease: studies in animal models].Rinsho Shinkeigaku. 2001 Dec;41(12):1157-9. Rinsho Shinkeigaku. 2001. PMID: 12235825 Review. Japanese.
-
Recent progress in gene therapy for Parkinson's disease.Curr Mol Med. 2012 Dec;12(10):1311-8. doi: 10.2174/156652412803833580. Curr Mol Med. 2012. PMID: 22834832 Review.
Cited by
-
Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy.J Neurosci. 2009 Feb 4;29(5):1544-53. doi: 10.1523/JNEUROSCI.4491-08.2009. J Neurosci. 2009. PMID: 19193901 Free PMC article.
-
Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.Mol Genet Metab. 2015 Feb;114(2):83-93. doi: 10.1016/j.ymgme.2014.09.011. Epub 2014 Oct 7. Mol Genet Metab. 2015. PMID: 25410058 Free PMC article. Review.
-
Toxin-induced models of Parkinson's disease.NeuroRx. 2005 Jul;2(3):484-94. doi: 10.1602/neurorx.2.3.484. NeuroRx. 2005. PMID: 16389312 Free PMC article. Review.
-
Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.Hum Gene Ther. 2004 Dec;15(12):1177-96. doi: 10.1089/hum.2004.15.1177. Hum Gene Ther. 2004. PMID: 15684695 Free PMC article.
-
The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease.Metab Brain Dis. 2022 Dec;37(8):2677-2685. doi: 10.1007/s11011-022-01021-5. Epub 2022 Sep 8. Metab Brain Dis. 2022. PMID: 36074314 Free PMC article.
References
-
- Mouradian M M, Chase T N. Exp Neurol. 1997;144:51–57. - PubMed
-
- Nutt J G, Obeso J A, Stocchi F. Trends Neurosci. 2000;23:S109–S115. - PubMed
-
- Horellou P, Brundin P, Kalen P, Mallet J, Björklund A. Neuron. 1990;5:393–402. - PubMed
-
- Fisher L J, Jinnah H A, Kale L C, Higgins G A, Gage F H. Neuron. 1991;6:371–380. - PubMed
-
- Wachtel S R, Bencsics C, Kang U J. J Neurochem. 1997;69:2055–2063. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical